| payload |
{"created_at":"2026-04-08T02:28:02.401 {"created_at":"2026-04-08T02:28:02.401723+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:a49907c8cdf7c025","evidence_event_ids":["evt_97b83bbabbc0"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1623526/0001849236-26-000004.txt","as_of":"2026-04-08T02:28:02.401723+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1623526/0001849236-26-000004.txt","company":"Stoke Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1623526/0001849236-26-000004.txt","article_chars":1778,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_c1ee9d7ec0268072","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1623526/0001849236-26-000004.txt","content_type":"text/plain","enriched_at":"2026-04-08T03:24:46.872852+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1623526/0001849236-26-000004.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1623526/0001849236-26-000004.txt","source_event_id":"evt_97b83bbabbc0","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"f7a6b74ea6e4d341","kind":"sec_filing","published_at":"20260407","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-07","2026-04-03","2026-04-02","2026-07-01","2026-10-01","2027-01-01","2027-04-01"],"entities":[{"asset_class":"equity","name":"Stoke Therapeutics, Inc.","relevance":"high","symbol":"STOK","type":"issuer"},{"asset_class":"person","name":"Clare Kahn","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"person","name":"Jonathan Allan","relevance":"low","symbol":"","type":"signatory"}],"event_type":"other","information_gaps":["The cleaned text does not explicitly state whether the Form 4 reflects an acquisition, grant, or other specific transaction code beyond the presence of a stock option (right to buy).","The filing\u2019s full table fields (e.g., transaction date, whether it is a grant vs exercise) are not fully interpretable from the provided cleaned snippet.","No prior-known state is included in the prompt, so the specific 'delta' versus prior disclosures cannot be determined from the provided text alone."],"key_facts":["SEC accession number: 0001849236-26-000004.","Form type: 4.","Conformed period of report: 20260403; filed as of date: 20260407.","Reporting owner: Clare Kahn (central index key: 0001849236).","Issuer: Stoke Therapeutics, Inc. (STOK; central index key: 0001623526).","Transaction/award type shown: \"Stock Option (Right to Buy)\".","Exercise price shown: 32.79.","Number of option shares shown: 30782 (appears as both 30782 and 30782 in the cleaned text).","Vesting terms disclosed: vesting as to 1/12 of the total award quarterly on the first calendar day of each July, October, January, and April; first tranche vesting on July 1, 2026; subject to continued service through each vesting date.","Signature line: /s/ Jonathan Allan, Attorney-in-Fact; dated 2026-04-07."],"numeric_claims":[{"label":"exercise_price_usd","value":"32.79"},{"label":"option_shares","value":"30782"},{"label":"first_vesting_date","value":"2026-07-01"},{"label":"vesting_frequency","value":"quarterly (1/12 each quarter)"}],"primary_claim":"On 2026-04-07, Stoke Therapeutics, Inc. filed Form 4 reporting a stock option award (right to buy) for reporting owner Clare Kahn with an exercise price of $32.79 and vesting beginning July 1, 2026.","relevance_score":0.45,"sentiment":"neutral","source_quality":"medium","summary":"Stoke Therapeutics, Inc. (STOK) filed a Form 4 on 2026-04-07 reporting a transaction by reporting owner Clare Kahn. The filing discloses a stock option (right to buy) with an exercise price of $32.79 and quarterly vesting starting July 1, 2026.","topics":["SEC filing","Form 4","stock option award","vesting schedule","insider transaction disclosure"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Stoke Therapeutics, Inc. \u00b7 Filed 20260407","ticker":"STOK","tickers":["STOK"],"title":"STOK filed 4","url":"https://www.sec.gov/Archives/edgar/data/1623526/0001849236-26-000004.txt"}}... |